Shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) shot up 2.9% during mid-day trading on Monday . The stock traded as high as $52.85 and last traded at $51.70, with a volume of 411,547 shares traded. The stock had previously closed at $50.23.

Several brokerages have issued reports on NBIX. Jefferies Group reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Sunday, May 8th. Robert W. Baird reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Sunday, May 8th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Tuesday, April 12th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $96.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, May 16th. Finally, TheStreet downgraded shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, July 14th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Neurocrine Biosciences has an average rating of “Buy” and a consensus price target of $63.90.

The firm’s market cap is $4.46 billion. The stock’s 50-day moving average is $46.75 and its 200 day moving average is $43.43.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.07. The business had revenue of $15 million for the quarter, compared to analysts’ expectations of $15.43 million. During the same period in the prior year, the company posted ($0.01) EPS. The firm’s revenue was down 24.1% on a year-over-year basis. On average, equities research analysts predict that Neurocrine Biosciences Inc. will post ($1.94) EPS for the current year.

In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $46.72, for a total value of $700,800.00. Following the transaction, the director now directly owns 15,464 shares in the company, valued at approximately $722,478.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Flint Obrien sold 25,000 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $45.00, for a total transaction of $1,125,000.00. Following the completion of the transaction, the insider now owns 80,044 shares in the company, valued at $3,601,980. The disclosure for this sale can be found here.

Other institutional investors have recently bought and sold shares of the company. I.G. Investment Management LTD. purchased a new position in Neurocrine Biosciences during the fourth quarter valued at $2,546,000. Russell Frank Co raised its position in Neurocrine Biosciences by 10.7% in the fourth quarter. Russell Frank Co now owns 53,358 shares of the company’s stock valued at $3,014,000 after buying an additional 5,148 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Neurocrine Biosciences by 7.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 134,303 shares of the company’s stock valued at $7,597,000 after buying an additional 9,793 shares during the last quarter. Principal Financial Group Inc. raised its position in Neurocrine Biosciences by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 160,233 shares of the company’s stock valued at $9,065,000 after buying an additional 449 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Neurocrine Biosciences by 16.1% in the fourth quarter. California Public Employees Retirement System now owns 184,200 shares of the company’s stock valued at $10,420,000 after buying an additional 25,600 shares during the last quarter.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.